NASDAQ:CING - Nasdaq - US17248W3034 - Common Stock - Currency: USD
4.27
+0.04 (+0.95%)
The current stock price of CING is 4.27 USD. In the past month the price decreased by -16.27%. In the past year, price decreased by -65.79%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY | ELI LILLY & CO | 67.21 | 829.40B | ||
NVO | NOVO-NORDISK A/S-SPONS ADR | 27.44 | 390.99B | ||
JNJ | JOHNSON & JOHNSON | 16.25 | 390.76B | ||
AZN | ASTRAZENECA PLC-SPONS ADR | 20.56 | 230.17B | ||
MRK | MERCK & CO. INC. | 11.71 | 226.40B | ||
NVS | NOVARTIS AG-SPONSORED ADR | 13.77 | 215.98B | ||
PFE | PFIZER INC | 8.46 | 149.04B | ||
SNY | SANOFI-ADR | 13.58 | 136.54B | ||
BMY | BRISTOL-MYERS SQUIBB CO | 48.97 | 113.23B | ||
GSK | GSK PLC-SPON ADR | 7.78 | 74.77B | ||
ZTS | ZOETIS INC | 27.1 | 72.39B | ||
TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.95 | 44.58B |
Cingulate Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Kansas City, Kansas and currently employs 13 full-time employees. The company went IPO on 2021-10-07. Cingulate Inc. is a biopharmaceutical company. The firm is focused on the development, manufacturing, and commercialization of pharmaceutical products that utilize its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles. The company focuses on the treatment of attention deficit/hyperactivity disorder (ADHD). The firm is in the development of two lead product candidates, such as CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). The Company’s CTx-1301 and CTx-1302 are being developed for the treatment of ADHD in the three core patient segments: children (ages 6-12), adolescents (ages 13-17), and adults (ages18+). In addition, the Company has a third product to treat anxiety, CTx-2103, in a formulation stage. Its CTx-1301, CTx-1302 and CTx-2103 drug candidates contain three releases of active pharmaceutical ingredient combined into one small tablet dosage form.
CINGULATE INC
1901 W. 47Th Place
Kansas City KANSAS US
Employees: 13
Company Website: https://www.cingulate.com/
Investor Relations: https://www.cingulate.com/investors
Phone: 19139422300
The current stock price of CING is 4.27 USD. The price increased by 0.95% in the last trading session.
The exchange symbol of CINGULATE INC is CING and it is listed on the Nasdaq exchange.
CING stock is listed on the Nasdaq exchange.
10 analysts have analysed CING and the average price target is 36.11 USD. This implies a price increase of 745.62% is expected in the next year compared to the current price of 4.27. Check the CINGULATE INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
CINGULATE INC (CING) has a market capitalization of 13.71M USD. This makes CING a Nano Cap stock.
CINGULATE INC (CING) currently has 13 employees.
CINGULATE INC (CING) has a support level at 4.26 and a resistance level at 4.52. Check the full technical report for a detailed analysis of CING support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
CING does not pay a dividend.
CINGULATE INC (CING) does not have a PE ratio as the earnings reported over the last twelve months were negative (-106.42).
The outstanding short interest for CINGULATE INC (CING) is 3.44% of its float. Check the ownership tab for more information on the CING short interest.
ChartMill assigns a fundamental rating of 2 / 10 to CING. CING scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months CING reported a non-GAAP Earnings per Share(EPS) of -106.42. The EPS increased by 72.8% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -120.39% | ||
ROE | -135.81% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 82% to CING. The Buy consensus is the average rating of analysts ratings from 10 analysts.